Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Exclusive: Astellas’ Xospata Provides Strong OS Benefits in Phase III Trial

Astellas Pharma’s blood cancer drug Xospata continues to show impressive results in the acute myeloid leukemia setting.

Read More »

Agios Receives FDA Breakthrough Therapy Designation for Tibsovo-Azacitidine Combination for AML

Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation for Tibsovo (ivosidenib) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Read More »

FDA Grants Orphan Drug Designation to Trovagene’s PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia

Trovagene Inc., a precision medicine biotechnology company, announced that the U.S. Food and Drug Administration granted an orphan drug designation to PCM-075 for the treatment of patients with acute myeloid leukemia (AML).

Read More »

FDA approves Novartis’ leukemia treatment

The U.S. FDA approved Novartis AG’s Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom